Publication
Contribution of haptoglobin phenotypic variation to the presence of hyperhomocysteinemia in type 2 diabetics with and without angiopathy
| dc.contributor.author | Ferreira, Isabel | |
| dc.contributor.author | Bicho, Manuel | |
| dc.contributor.author | Valente, Ana | |
| dc.date.accessioned | 2025-04-04T11:42:07Z | |
| dc.date.available | 2025-04-04T11:42:07Z | |
| dc.date.issued | 2024 | |
| dc.description | © The Author(s), under exclusive licence to Springer Nature Limited 2024 | pt_PT |
| dc.description.abstract | Background/aim: The genetic polymorphism of haptoglobin (Hp) has been associated with several cardiovascular risk factors, but a possible relationship between Hp phenotypic variation and increased levels of homocysteine (Hcy) and cysteine (Cy) is still unknown. The objective of this study is to evaluate the relationship between the Hp polymorphism and hyperhomocysteinemia (HHcy) and hypercysteinemia (HCy) in type 2 diabetics (T2D) with and without angiopathy (AGP). Methods: A case-control study was carried out on 293 adults: Group I (GI) - 75 subjects with T2D and AGP; Group II (GII) - 75 subjects with T2D without AGP; Group III (GIII) - 143 controls. Plasma levels of Hcy, Cy and vitamin B6 were measured by high performance liquid chromatography (HPLC) and vitamins B9 and B12 determined by electrochemiluminescence (ECL). The Hp polymorphism was identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and peroxidase staining. The results were analyzed in SPSS®, version 26.0 with a significance of 95%. Results: Mean Hcy concentrations were significantly lower in carriers of the Hp2-2 phenotype (6.14 µM; p = 0.046) compared to the other genotypes. The presence of Hp2-1 is associated with an approximately 3.3 times greater probability of occurrence of HHcy (p = 0.015) and 3.7 times greater probability occurrence of HCy (p = 0.021) in T2D with AGP. Conclusion: The presence of the Hp2-1 phenotype is associated with the predisposition of HHcy and HCy in individuals with T2D and AGP, possibly through a positive heterosis mechanism. Carriers of the Hp2-2 phenotype appear to have a greater activation of the transsulfuration pathway in the Hcy cycle and consequent protection for its accumulation. | pt_PT |
| dc.description.sponsorship | This study was finanially supported by the research project PIC/IC/82957/2007 from Foundation for Science and Technology (FCT) and by Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P. (Lisboa, Portugal). This study had also the financial support of the FCT for Environmental Health Institute (references UIDB/04295/2020 and UIDP/04295/2020). Ana Valente acknowledges the financial support received from FCT, through the PhD grant (SFRH/BD/16166/2004/5E4M). | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Eur J Clin Nutr. 2025 Mar;79(3):266-272 | pt_PT |
| dc.identifier.doi | 10.1038/s41430-024-01524-7 | pt_PT |
| dc.identifier.eissn | 1476-5640 | |
| dc.identifier.issn | 1476-5640 | |
| dc.identifier.uri | http://hdl.handle.net/10400.5/100004 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Springer Nature | pt_PT |
| dc.relation | SFRH/BD/16166/2004/5E4M | pt_PT |
| dc.relation | Environmental Health Institute | |
| dc.relation.publisherversion | https://www.nature.com/ejcn/ | pt_PT |
| dc.title | Contribution of haptoglobin phenotypic variation to the presence of hyperhomocysteinemia in type 2 diabetics with and without angiopathy | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.awardTitle | Environmental Health Institute | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT/5646-ICCMS/PIC%2FIC%2F82957%2F2007/PT | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT/Concurso de avaliação no âmbito do Programa Plurianual de Financiamento de Unidades de I&D (2017%2F2018) - Financiamento Base/UIDB%2F04295%2F2020/PT | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04295%2F2020/PT | |
| oaire.citation.endPage | 272 | pt_PT |
| oaire.citation.issue | 3 | pt_PT |
| oaire.citation.startPage | 266 | pt_PT |
| oaire.citation.title | European Journal of Clinical Nutrition | pt_PT |
| oaire.citation.volume | 79 | pt_PT |
| oaire.fundingStream | 5646-ICCMS | |
| oaire.fundingStream | Concurso de avaliação no âmbito do Programa Plurianual de Financiamento de Unidades de I&D (2017/2018) - Financiamento Base | |
| oaire.fundingStream | 6817 - DCRRNI ID | |
| person.familyName | Bicho | |
| person.familyName | Valente | |
| person.givenName | Manuel | |
| person.givenName | Ana | |
| person.identifier.ciencia-id | 9512-8D22-1B28 | |
| person.identifier.ciencia-id | FE1E-5A9B-EC3D | |
| person.identifier.orcid | 0000-0002-5773-5687 | |
| person.identifier.orcid | 0000-0003-4039-4326 | |
| person.identifier.scopus-author-id | 7004153755 | |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| rcaap.rights | restrictedAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | c61e4f7e-28b3-47b4-bc5d-677b73fc3aec | |
| relation.isAuthorOfPublication | 5cc9e5eb-aa95-469e-a33f-211594b2f82b | |
| relation.isAuthorOfPublication.latestForDiscovery | 5cc9e5eb-aa95-469e-a33f-211594b2f82b | |
| relation.isProjectOfPublication | 08fddb66-87e6-4c4e-9240-6bc00f48f9c8 | |
| relation.isProjectOfPublication | f0106330-79bf-440f-937b-3c389c4b0ecc | |
| relation.isProjectOfPublication | e1b50370-2ac3-497c-a2c2-72f33f50643e | |
| relation.isProjectOfPublication.latestForDiscovery | 08fddb66-87e6-4c4e-9240-6bc00f48f9c8 |
